USPTO Examiner HAMMELL NEIL P - Art Unit 1636

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
17102050METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONNovember 2020March 2021Allow400YesNo
17102059METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONNovember 2020April 2021Allow400NoNo
17084014METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONOctober 2020September 2021Allow1110NoNo
17084023METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONOctober 2020March 2021Allow500NoNo
17079070METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONOctober 2020November 2021Allow1320NoNo
16935007METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONJuly 2020November 2020Allow400NoNo
16935011METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONJuly 2020February 2021Allow700NoNo
16932294OPTIMIZED PROTEIN LINKERS AND METHODS OF USEJuly 2020May 2021Allow911NoNo
16915087METHODS FOR DECONTAMINATING CIRCUITS FOR PRODUCING GLUCOSE POLYMERS AND HYDROLYSATES OF GLUCOSE POLYMERSJune 2020September 2023Abandon3810NoNo
16914203MODIFIED CASCADE RIBONUCLEOPROTEINS AND USES THEREOFJune 2020February 2021Allow701YesNo
16898161METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONJune 2020November 2021Abandon1720YesNo
16898186METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONJune 2020August 2023Abandon3801NoNo
16898197METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONJune 2020August 2023Abandon3801NoNo
16896731TYPE V CRISPR/CAS EFFECTOR PROTEINS FOR CLEAVING SSDNAS AND DETECTING TARGET DNASJune 2020June 2021Allow1211NoNo
16892631METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONJune 2020July 2020Allow200YesNo
16892663METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONJune 2020July 2020Allow200NoNo
16864220METHODS AND USE OF INDUCING APOPTOSIS IN CANCER CELLSMay 2020October 2024Abandon5410NoNo
16844059MODIFIED BINDING PROTEINS INHIBITING THE VEGF-A RECEPTOR INTERACTIONApril 2020November 2024Abandon5610NoNo
16825807METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONMarch 2020August 2023Abandon4101NoNo
16643402METHOD FOR MODIFYING TARGET SITE IN DOUBLE-STRANDED DNA IN CELLFebruary 2020January 2021Allow1111NoNo
16790368METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONFebruary 2020June 2020Allow400NoNo
16789049CASZ COMPOSITIONS AND METHODS OF USEFebruary 2020September 2021Allow1920YesNo
16781888ALGORITHMS FOR DISEASE DIAGNOSTICSFebruary 2020November 2024Abandon5701NoNo
16659277SINGLE NUCLEOTIDE POLYMORPHISMS (SNP) AND ASSOCIATION WITH RESISTANCE TO IMMUNE TOLERANCE INDUCTIONOctober 2019August 2023Abandon4601NoNo
16577740METHODS AND COMPOSITIONS FOR DETECTING A TARGET RNASeptember 2019May 2022Allow3230YesNo
16577696METHODS AND COMPOSITIONS FOR DETECTING A TARGET RNASeptember 2019May 2022Allow3230YesNo
16560711METHODS AND COMPOSITIONS FOR CLASSIFICATION OF SAMPLESSeptember 2019November 2024Abandon6001NoNo
16554225MODIFIED CASCADE RIBONUCLEOPROTEINS AND USES THEREOFAugust 2019May 2020Allow900YesNo
16455342GENOMIC PROBESJune 2019September 2021Allow2640YesNo
16461992COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING EGFR OR HER2 EXON 20 MUTATIONSMay 2019May 2022Allow3611YesNo
16343364SYSTEMS AND METHODS FOR DETECTING DISSEMINATED OR CIRCULATING CELLS OR DNAApril 2019July 2022Abandon3911NoNo
16385383METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONApril 2019February 2023Allow4600NoNo
16383433METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONApril 2019March 2020Allow1100YesNo
16383412METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONApril 2019February 2020Allow1000NoNo
16383443METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONApril 2019January 2020Allow900NoNo
16383422METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONApril 2019January 2020Allow900NoNo
16382100METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONApril 2019December 2019Allow800NoNo
16382096METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONApril 2019November 2019Allow700NoNo
16382097METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONApril 2019December 2019Allow800NoNo
16382093METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONApril 2019October 2019Allow600NoNo
16380758METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONApril 2019October 2019Allow700NoNo
16380781METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONApril 2019October 2019Allow700NoNo
16278438OVEREXPRESSION OF FOXC1 TO TREAT CORNEAL VASCULARIZATIONFebruary 2019January 2021Allow2320NoNo
16277090METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONFebruary 2019September 2019Allow700NoNo
16276348METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONFebruary 2019August 2019Allow600YesNo
16276352METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONFebruary 2019March 2020Allow1310NoNo
16276356METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONFebruary 2019August 2019Allow600NoNo
16276343METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONFebruary 2019June 2019Allow400YesNo
16274770SYNTHETIC TRANSCRIPTIONAL REGULATOR COMPOSITIONS AND METHODSFebruary 2019March 2022Abandon3730NoNo
16262257TYPE V CRISPR/CAS EFFECTOR PROTEINS FOR CLEAVING SSDNAS AND DETECTING TARGET DNASJanuary 2019August 2023Abandon5410NoNo
16201855METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONNovember 2018May 2019Allow600YesNo
16201862METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONNovember 2018February 2020Allow1410YesNo
16201853METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONNovember 2018May 2019Allow600YesNo
16201865METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONNovember 2018February 2020Allow1410YesNo
16201836METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONNovember 2018May 2019Allow610YesNo
16201848METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONNovember 2018April 2019Allow500NoNo
16189683Combinatorial Metabolic Engineering Using a CRISPR SystemNovember 2018September 2023Abandon5821NoNo
16181679DIAGNOSTIC SEQUENCING VIA TABLETSNovember 2018July 2022Abandon4421NoNo
16124252MYCOBACTERIOPHAGES CAPABLE OF DELIVERING AUTO-LUMINESCENT ELEMENTS AND USES THEREOFSeptember 2018April 2021Allow3120YesNo
16105502Fusion Polymerase and Method for Using the SameAugust 2018December 2022Allow5210NoNo
16054513RNA-GUIDED NUCLEIC ACID MODIFYING ENZYMES AND METHODS OF USE THEREOFAugust 2018August 2019Allow1321NoNo
16033832TRANSFORMANT, AND METHOD FOR PRODUCING TRANSFERRINJuly 2018July 2019Allow1210YesNo
16033016METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONJuly 2018March 2019Allow810NoNo
16033002METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONJuly 2018July 2019Allow1211YesNo
16033005METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONJuly 2018July 2019Allow1211YesNo
16021700MATERIALS AND METHODS FOR DETERMINING CANCER RISKJune 2018September 2021Allow3900YesNo
16007541RARE NUCLEIC ACID DETECTIONJune 2018May 2023Abandon5940NoNo
16007498PLASMA/SERUM TARGET ENRICHMENTJune 2018May 2022Abandon4730NoNo
16007427NEGATIVE-POSITIVE ENRICHMENT FOR NUCLEIC ACID DETECTIONJune 2018January 2023Abandon5540NoNo
16007510SELECTIVE PROTECTION OF NUCLEIC ACIDSJune 2018May 2023Abandon5940NoNo
16060759METHODS AND COMPOSITIONS FOR ENHANCED NUCLEASE-MEDIATED GENOME MODIFICATION AND REDUCED OFF-TARGET SITE EFFECTSJune 2018April 2022Abandon4630NoNo
16002602Methods and Compositions for Modifying a Single Stranded Target Nucleic AcidJune 2018July 2019Allow1410YesNo
15965921COMPOSITIONS AND METHODS OF ENGINEERED CRISPR-CAS9 SYSTEMS USING SPLIT-NEXUS CAS9-ASSOCIATED POLYNUCLEOTIDESApril 2018July 2021Allow3900YesNo
15965598METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONApril 2018March 2022Abandon4601YesNo
15965603METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONApril 2018March 2022Abandon4601NoNo
15959782METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONApril 2018March 2022Abandon4701YesNo
15959762METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONApril 2018February 2022Abandon4601NoNo
15959802METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONApril 2018March 2022Abandon4701YesNo
15959715METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONApril 2018March 2022Abandon4701NoNo
15959735METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONApril 2018February 2022Abandon4601NoNo
15959498RECOMBINANT BACTERIAL HOST CELL FOR PROTEIN EXPRESSIONApril 2018October 2021Allow4260YesNo
15945388Oligonucleotides and Methods for Detecting KRAS and PIK3CA MutationsApril 2018February 2021Allow3402NoNo
15765420METHODS AND COMPOSITIONS FOR GENERATING CRISPR/CAS GUIDE RNASApril 2018November 2021Allow4301NoNo
15934945NUCLEOBASE EDITORS COMPRISING NUCLEIC ACID PROGRAMMABLE DNA BINDING PROTEINSMarch 2018October 2021Allow4321YesNo
15925544Methods and Compositions for RNA-Directed Target DNA Modification and for RNA-Directed Modulation of TranscriptionMarch 2018June 2019Allow1520YesNo
15920222METHODS AND COMPOSITIONS FOR DETECTING A TARGET RNAMarch 2018September 2019Allow1820YesNo
15915020METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTIONMarch 2018December 2020Abandon3301NoNo
15897455METHOD OF EVALUATING CELLULITE AND METHOD OF EVALUATING CELLULITE-EFFECTIVE DRUG USING FIBULIN-3 AND/OR SARCOGLYCAN GAMMA AS AN INDICATORFebruary 2018April 2020Allow2600YesNo
15897089TYPE V CRISPR/CAS EFFECTOR PROTEINS FOR CLEAVING SSDNAS AND DETECTING TARGET DNASFebruary 2018December 2018Allow1011NoNo
15751426IMPROVEMENTS IN OR RELATING TO DNA RECOMBINATIONFebruary 2018October 2020Allow3331YesNo
15890561DNA Editing Using Relatively Long Single-Stranded DNA and CRISPR/Cas9 to Increase Success Rate in Methods for Preparing Transgenic Embryos and AnimalsFebruary 2018September 2022Allow5560YesYes
15884329METHOD FOR PREPARING RECOMBINANT ADENO-ASSOCIATED VIRUSJanuary 2018September 2020Allow3120NoNo
15883955IMAGING INDIVIDUAL MRNA MOLECULES USING MULTIPLE SINGLY LABELED PROBESJanuary 2018May 2021Abandon4020YesNo
15863005COMPOSITIONS AND METHODS IDENTIFYING AND USING STEM CELL DIFFERENTIATION MARKERSJanuary 2018December 2021Abandon4721YesNo
15839817GENOME EDITING DETECTIONDecember 2017August 2022Abandon5641YesNo
15839820GENOME EDITING ENHANCEMENTDecember 2017November 2021Allow4731YesNo
15735941NEW CRISPR ASSAYSDecember 2017July 2020Abandon3101YesNo
15829445METHODS, COMPOSITIONS, AND KITS FOR NUCLEIC ACID ANALYSISDecember 2017July 2020Abandon3121NoNo
15821456METHODS OF PREDICTING OSTEOARTHRITISNovember 2017July 2021Abandon4421NoNo
15574748REPORTER CAS9 VARIANTS AND METHODS OF USE THEREOFNovember 2017September 2022Abandon5821NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HAMMELL, NEIL P.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
9
Examiner Affirmed
5
(55.6%)
Examiner Reversed
4
(44.4%)
Reversal Percentile
66.8%
Higher than average

What This Means

With a 44.4% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
45
Allowed After Appeal Filing
8
(17.8%)
Not Allowed After Appeal Filing
37
(82.2%)
Filing Benefit Percentile
22.7%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 17.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner HAMMELL, NEIL P - Prosecution Strategy Guide

Executive Summary

Examiner HAMMELL, NEIL P works in Art Unit 1636 and has examined 417 patent applications in our dataset. With an allowance rate of 39.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.

Allowance Patterns

Examiner HAMMELL, NEIL P's allowance rate of 39.3% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by HAMMELL, NEIL P receive 2.44 office actions before reaching final disposition. This places the examiner in the 67% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by HAMMELL, NEIL P is 35 months. This places the examiner in the 38% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +40.3% benefit to allowance rate for applications examined by HAMMELL, NEIL P. This interview benefit is in the 86% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 9.5% of applications are subsequently allowed. This success rate is in the 6% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 18.4% of cases where such amendments are filed. This entry rate is in the 23% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 111.1% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 80% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 62.5% of appeals filed. This is in the 40% percentile among all examiners. Of these withdrawals, 73.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 42.2% are granted (fully or in part). This grant rate is in the 32% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.4% of allowed cases (in the 73% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.